Neurol. praxi. 2014;15(2):65-67
New perspective treatment of multiple sclerosis
- II. neurologická klinika SZU, FNsP F. D. Roosevelta, Banská Bystrica
The paper reviews the possible perspectives of new treatment strategies for multiple sclerosis (MS) with a focus on oral agents, monoclonal antibodies as well as DNA vaccines. A new generation of immunomodulatory drugs has been shown to be more effective for RR forms of MS in comparison with the established first-line DMT; however, it is still not beneficial in treating the progressive stage of the disease. The goal of new treatment strategies for MS is the introduction of individual therapy aimed at individual activity, disease aggressiveness, and specific immunology in particular patients. The review presents the results of preclinical and early clinical trials as well as the safety and tolerability of individual agents.
Keywords: multiple sclerosis, immunomodulatory therapy, monoclonal antibodies, T lymphocytes, B lymphocytes
Published: May 10, 2014 Show citation
References
- Buck D, Hemmer B. Treatment of multiple sclerosis: current concepts and future perspectives. J Neurol. 2011;258 (10): 1747-1762.
Go to original source... 
Go to PubMed... - Comi G, Abramsky O, Arbizu T, et al. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 9-month double-blind active extension of the multiplecenter, randomized, double-blind, parallel-group placebo-controlled study (abstract. P31). Mult Scler. 2008;14 (1 Suppl.): S37-8.
- Connor, P, Wolinsky, JS, Confavreux, C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365 (14): 1293-303. Go to original source... Go to PubMed...
- Fissolo N, Montalban X, Comabella M. DNA-based vaccines for multiple sclerosis: current status and future directions. Clin Immunol. 2012;142 (1): 76-83. Go to original source... Go to PubMed...
- Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group. B-cell depletion with rituximab in relapsing remitting multiple sclerosis. N Engl J Med. 2008; 358(7): 676-688. Go to original source... Go to PubMed...
- Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, Chen PC. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci. 2008; 1147: 61-69. Go to original source... Go to PubMed...
- Kappos L, Giovannoni G, Gold R, Fox RJ, Phillips JT, Hotermans C, Zhang A, Viglietta V, Miller DH. Timecourse of treatment effects of BG-12 (Dimethyl Fumarate) in MS (poster DX40). Neurology. 2013;80 (1 meeting abstracts): S41.005.
- Katz Sand IB, Kreiger S. Emerging strategies for the treatment of multiple sclerosis. Future Neurol. 2012; 7(2): 193-207.. Go to original source...
- Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 2010; 10(11): 1026-1034. Go to original source... Go to PubMed...
- Krieger S. Multiple sclerosis therapeutic pipeline: opportunities and challenges. Mt Sinai J Med. 2011; 78(2): 192-206. Go to original source... Go to PubMed...
- Martin R. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis. Neurodegener Dis. 2008; 5(1): 23-26. Go to original source... Go to PubMed...
- O'Connor, PW, Li D, Freedman, MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006; 66(6): 894-900. Go to original source... Go to PubMed...
- O'Connor PW, Wolinsky J, Confavreux C, Comi G, Kappos L, Olsson T, Benzerdjeb H, Wamil B, Wang L, Miller A, Freedman MS. A placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: clinical efficacy and safety outcomes. Abstract P.79. Mult. Scler. 2010; 16(10 suppl.): S23. Abstract P.79.
- Rozman, B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet. 2002; 41(6): 421-430. Go to original source... Go to PubMed...
- Saidha S, Eckstein C, Calabresi PA. New and emerging disease modifying therapies for multiple sclerosis. Ann. N.Y. Acad. Sci. 2012; 1247: 117-137. Go to original source... Go to PubMed...